

This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Continue or find out more.



## Progesterone supplementation to reduce the risk of spontaneous preterm birth

Author: [Errol R Norwitz, MD, PhD, MBA](#)

Section Editor: [Charles J Lockwood, MD, MHCM](#)

Deputy Editor: [Vanessa A Barss, MD, FACOG](#)

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

**Literature review current through:** Jun 2018. | **This topic last updated:** Feb 16, 2018.

**INTRODUCTION** — Preterm birth (delivery prior to 37 weeks or 259 days of gestation) complicates 1 in 8 deliveries in the United States, but accounts for over 85 percent of all perinatal morbidity and mortality. Efforts to delay delivery in women presenting with acute preterm labor have been largely unsuccessful. For this reason, much attention has focused on preventive strategies, such as [progesterone](#) supplementation.

Although supplemental [progesterone](#) appears to be effective in preventing preterm birth in some high-risk women, it should not be seen as a panacea. For example, even if all pregnant women in the United States with a history of preterm birth receive progesterone prophylaxis, it is estimated that the risk of preterm birth would be reduced by 20 percent and the absolute preterm birth rate would be reduced by only 0.01 percent because most preterm births are not recurrences and prophylaxis has limited efficacy [1-4]. If women with a short cervix are also identified and treated, an additional absolute risk reduction of 0.02 percent would be achieved [4].

This topic will review issues related to use of [progesterone](#) for prevention of preterm birth. Progesterone supplementation is only one component of risk reduction. Risk factors for preterm birth and other potential interventions for reducing risk are discussed separately. (See "[Preterm birth: Risk factors, interventions for risk reduction, and maternal prognosis](#)".)

**ROLE OF PROGESTERONE IN PREGNANCY MAINTENANCE** — [Progesterone](#) is a steroid hormone initially produced by the corpus luteum. In early pregnancy, progesterone is critical for pregnancy maintenance until the placenta takes over this function at 7 to 9 weeks of gestation, and its name is derived from this function: pro-gestational steroidal ketone. Indeed, removal of the source of progesterone (the corpus luteum) [5] or administration of a progesterone receptor antagonist [6] readily induces abortion before 7 weeks (49 days) of gestation.

[Progesterone](#) appears to be important in maintaining uterine quiescence in the latter half of pregnancy; however, the mechanism is unclear [7-9]. Functional withdrawal of progesterone activity at the level of the uterus appears to occur proximate to the onset of labor both at term and preterm, without a significant change in serum progesterone levels in the weeks preceding labor [7-14]. Progesterone also prevents apoptosis in fetal membrane explants under both basal and pro-inflammatory conditions [15,16] and thus may protect the membranes from preterm premature rupture and, in turn, preterm birth.

[Progesterone](#) supplementation may enhance these actions, which are likely mediated via progesterone-receptors [17]. Other mechanisms may also be involved (eg, alteration in the immune response).

**EFFICACY OF PROGESTERONE FOR PREVENTION OF PRETERM BIRTH** — The efficacy of [progesterone](#) supplementation for prevention of preterm birth depends primarily on appropriate patient selection ([table 1](#)). In vitro and animal research suggest that the type of progestin, formulation, dose, route of

delivery, and plasma concentration (which varies among patients receiving progestins) also impact efficacy [18-20]. Emerging evidence suggests that the specific pathogenetic pathway leading to preterm birth is important as well [21,22]. These factors likely played a role in the discordant findings reported in the trials discussed below.

**Pregnancies likely to benefit from progesterone supplementation** — [Progesterone](#) supplementation appears to reduce the rate of spontaneous singleton preterm birth in women who have had a previous spontaneous preterm singleton birth and in women with a short cervix on ultrasound examination in the current pregnancy. Neonatal morbidity and neonatal mortality are also reduced.

Since spontaneous preterm birth is likely the final common pathway of several pathogenic processes, a single intervention such as [progesterone](#) supplementation is unlikely to benefit all women at risk. A logistic regression analysis demonstrated significant treatment-genotype interactions, which could result in either a beneficial or harmful treatment response [23]. Studies have also found that women with certain characteristics, such as vaginal bleeding, gonorrhea, or chlamydia in the current pregnancy; a late preterm birth in a past pregnancy; or penultimate preterm birth, are less likely to have a significant risk reduction [21,22].

**Spontaneous singleton preterm birth in prior pregnancy** — A 2013 meta-analysis analyzed 39 randomized trials of prenatal [progesterone](#) administration for prevention of preterm birth in women at increased risk of preterm birth by various criteria [24]. For women with a past history of spontaneous preterm birth (11 trials, n = 1899 women), progesterone supplementation resulted in lower risks for preterm birth and some neonatal morbidities compared with placebo/no treatment:

- Birth <34 weeks (relative risk [RR] 0.31, 95% CI 0.14-0.69)
- Birth <37 weeks (RR 0.55, 95% CI 0.42-0.74)
- Neonatal death (RR 0.45, 95% CI 0.27-0.76)
- Use of assisted ventilation (RR 0.40, 95% CI 0.18-0.90)
- Necrotizing enterocolitis (RR 0.30, 95% CI 0.10-0.89)
- Neonatal intensive care unit admission (RR 0.24, 95% CI 0.14-0.40)

Differences in risks for intraventricular hemorrhage, neonatal sepsis, and retinopathy of prematurity were not statistically significant.

**Seminal trials** — The following two trials are the seminal trials supporting the benefit of [progesterone](#) supplementation for prevention of recurrent preterm birth, and were included in the meta-analysis described above [24]. In contrast, the OPPTIMUM trial, which was published after this meta-analysis, found no significant improvement in primary obstetric, neonatal, or childhood outcomes with vaginal progesterone supplementation [25].

**Maternal fetal medicine units network trial (hydroxyprogesterone caproate injection)** — Meis and co-investigators randomly assigned 459 women with a documented history of spontaneous singleton preterm delivery <37 completed weeks to weekly intramuscular injections of [hydroxyprogesterone caproate](#) (250 mg) or placebo beginning at 16 to 20 weeks of gestation and continuing until 36 weeks [3]. Active prophylaxis significantly reduced the risk of delivery at all gestational ages studied:

- <37 weeks (36 versus 55 percent in the placebo group [RR 0.66; 95% CI, 0.54-0.81]),
- <35 weeks (21 versus 31 percent [RR 0.67; 95% CI, 0.48-0.93])
- <32 weeks (11 versus 20 percent [RR 0.58; 95% CI, 0.37-0.91])

Infants from [progesterone](#) supplemented pregnancies had less perinatal morbidity, with significantly reduced rates of necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental oxygen. There was no evidence of virilization of female offspring, which is a theoretic concern of this therapy.

Secondary analysis of these data found that women with a history of a prior spontaneous preterm birth <34 completed weeks were most likely to benefit [26].

The placebo group had a particularly high rate of preterm birth, which limits the generalizability of these findings to women at lower risk of recurrent preterm birth and raises a concern about potential imbalance among study groups despite randomization.

**Brazilian trial (progesterone gel vaginally)** — da Fonseca and co-investigators randomly assigned 142 women at high-risk for preterm delivery (based on at least one previous spontaneous singleton preterm birth, prophylactic cervical cerclage, or uterine malformation) to daily supplementation with [progesterone](#) vaginal suppositories (100 mg) or placebo from 24 through 34 weeks of gestation [2]. Active prophylaxis significantly reduced the risk of delivery at all gestational ages studied:

- <37 weeks (14 versus 29 percent in the placebo group)
- <34 weeks (3 versus 19 percent in the placebo group)

By monitoring all patients with an external tocodynamometer once a week for 60 minutes, the investigators were also able to demonstrate a significant difference in the frequency of spontaneous uterine contractions between the two groups, suggesting that [progesterone](#) supplementation exerts its effect by maintaining uterine quiescence in the latter half of pregnancy.

**OPPTIMUM (progesterone capsules vaginally)** — In OPPTIMUM (vaginal [progesterone](#) prophylaxis for preterm birth study), 1228 women at high risk for preterm birth were randomly assigned to receive either vaginal progesterone 200 mg daily or matching placebo, beginning at 22 to 24 weeks of gestation and ending at 34 weeks [25]. Inclusion criteria were previous spontaneous birth at ≤34 weeks, cervical length ≤25 mm, and/or a positive fetal fibronectin test combined with clinical risk factors for preterm birth (eg, history of second-trimester loss, preterm premature rupture of membranes, or cervical procedure to treat cervical intraepithelial neoplasia).

Major findings were:

- Vaginal [progesterone](#) supplementation did **not** significantly reduce the:
  - Primary obstetric outcome "fetal death or birth before 34 weeks" (adjusted odds ratio [OR] 0.86, 95% CI 0.61-1.22)
  - Primary neonatal outcome "death, brain injury, or bronchopulmonary dysplasia" (adjusted OR 0.62, 95% CI 0.38-1.03)
  - Primary childhood outcome "standardized cognitive score at two years of age" (difference in means -0.48, 95% CI -2.77 to 1.81)
- Although primary obstetric and neonatal composite outcomes were not improved, vaginal [progesterone](#) supplementation resulted in fewer neonatal deaths (1/600 versus 6/537; unadjusted OR 0.17, 95% CI 0.06-0.49) and a reduction in brain injury on neonatal ultrasound (3 versus 6 percent; unadjusted OR 0.50, 0.31-0.84).
- In subgroup analysis, "women with a history of a prior spontaneous preterm birth" had no significant treatment effect in obstetric and childhood outcomes, but a potential treatment effect was noted for the composite neonatal outcome (OR 0.48, 95% CI 0.29-0.79; P-interaction 0.053).

The study was well-designed, well-executed, and had a sample size larger than all previously published studies combined. Two-thirds of women in the [progesterone](#) group were compliant (ie,  $\geq 80$  percent of medication was taken).

While vaginal [progesterone](#) supplementation in this high-risk cohort did not significantly reduce preterm birth, it did reduce the frequency of neonatal death and sonographic evidence of brain injury. Why these early benefits did not lead to a difference in mortality or neurodevelopmental outcome at two years is unclear. The role of postnatal factors on these outcomes requires further study. In addition, the standardized cognitive score is a limited measure of neurodevelopmental outcome and may not have captured more subtle behavioral and cognitive outcomes.

The subsequent PROGRESS trial found no significant reduction in neonatal respiratory distress syndrome or secondary outcomes (other neonatal and maternal morbidities related to preterm birth) with vaginal [progesterone](#) supplementation [27]. These trials do not change the author's treatment approach ([table 1](#)). The results are concordant with findings from trials showing a benefit of [hydroxyprogesterone caproate](#) in patients with prior spontaneous preterm birth (see '[Maternal fetal medicine units network trial \(hydroxyprogesterone caproate injection\)](#)' above) and with a systematic review showing a benefit of vaginal progesterone in patients with a short cervix. (See '[Short cervix in current pregnancy](#)' below.)

**Short cervix in current pregnancy** — Cervical shortening is a known risk factor for preterm birth in both low- and high-risk populations (see "[Second-trimester evaluation of cervical length for prediction of spontaneous preterm birth](#)").

A 2018 systematic review and meta-analysis of individual patient data from randomized trials (including OPPTIMUM) found that vaginal [progesterone](#) supplementation reduced the risk of preterm birth and neonatal morbidity and mortality in singleton gestations with midtrimester cervical length  $\leq 25$  mm [28]. For example, compared with placebo, vaginal progesterone:

- Reduced spontaneous preterm birth  $< 34$  weeks of gestation (15 versus 20 percent, RR 0.72, 95% CI 0.55-0.95; five trials, 974 women), as well as spontaneous preterm birth before 28, 30, 32, 35, and 36 weeks
- Reduced respiratory distress syndrome (RR 0.47, 95% CI 0.27-0.81)
- Reduced composite neonatal morbidity and mortality (RR 0.59, 95% CI 0.38-0.91)
- Reduced birth weight  $< 1500$  g (RR 0.62, 95% CI 0.44-0.86)
- Reduced admission to the neonatal intensive care unit (RR 0.68, 95% CI 0.53-0.88)

Neurodevelopmental outcomes at two years of age were similar for vaginal [progesterone](#) and placebo groups.

Use of vaginal [progesterone](#) appears to be a critical factor for preventing preterm birth in women with a short cervix. In contrast to the above systematic review and meta-analysis of trials of vaginal progesterone [28], two trials in which women with singleton gestations and a short cervical length were randomly assigned to weekly intramuscular [hydroxyprogesterone caproate](#) (250 mg or 500 mg) or placebo through 36 weeks reported that treatment with hydroxyprogesterone caproate did not reduce the risk of preterm birth [29,30]. In addition to chance, methodological issues may have played a role. For example, both trials were stopped before completion because of lack of efficacy at the scheduled interim analysis. Also, one trial was limited to nulliparous women with a short cervix while the other included women with both a short cervix and risk factors for preterm birth (history of preterm delivery, cervical surgery, uterine malformation, or prenatal diethylstilbestrol exposure).

It is also possible that differences in the pharmacologic actions of the two progesterones may account for differences in effectiveness in women with a short cervix. Vaginal [progesterone](#) clearly inhibits cervical

ripening; the effect of 17OHPC on cervical ripening is less clear [31].

**Pregnancies where the benefit of progesterone supplementation is unclear** — The benefit of [progesterone](#) supplementation in women at high risk of preterm birth, but without a short cervix or a prior history of singleton preterm birth, is not supported by strong evidence. Some of these clinical scenarios are reviewed below.

**Positive fetal fibronectin test** — Although a positive cervicovaginal fetal fibronectin (fFN) test is a risk factor for preterm birth, minimal information on use of [progesterone](#) supplementation in such women is available. In OPPTIMUM, women with a positive fFN test and risk factors for preterm birth were included in the study population [25]. Progesterone supplementation did not improve obstetric, neonatal, or childhood outcomes in this trial. (See '[OPPTIMUM \(progesterone capsules vaginally\)](#)' above.)

**Cerclage** — In women with a prior preterm birth, continuing [hydroxyprogesterone caproate](#) supplementation after placement of a cerclage has not been proven to be useful, but available data are limited to secondary analysis of one underpowered trial. (See "[Cervical insufficiency](#)", [section on 'Cerclage placement and use of progesterone supplementation'](#).)

**Preterm premature rupture of membranes** — [Progesterone](#) supplementation is not beneficial in women with preterm premature rupture of membranes (PPROM) in the current pregnancy. In two placebo-controlled, randomized trials of women with PPRM at 20 to 30 weeks of gestation, weekly injection of [hydroxyprogesterone caproate](#) did not extend the latent period before delivery or reduce perinatal morbidity [32,33].

In contrast, women with a history of preterm birth due to PPRM appear to benefit from [progesterone](#) supplementation in subsequent pregnancies; these women were included in the prior randomized trials of the efficacy of progesterone supplementation in women with prior preterm birth [2,3]. As discussed above (see '[Role of progesterone in pregnancy maintenance](#)' above), progesterone appears to prevent apoptosis in fetal membranes in vitro under both basal and pro-inflammatory conditions [15], thereby providing a mechanism by which progesterone supplementation may prevent recurrent PPRM and preterm birth.

**Threatened preterm labor** — A 2014 meta-analysis of data from four small randomized trials in women with threatened or established preterm labor found that [progesterone](#) therapy did not reduce preterm birth <34 weeks or delivery of infants <2500 grams, but a possible reduction in delivery before 37 weeks was observed [34].

**After threatened preterm labor** — The use of [progesterone](#) in women who remain undelivered after an episode of threatened preterm labor is investigational and most providers (including the author) do not routinely recommend progesterone supplementation for maintenance tocolysis. Randomized trials evaluating various types of progesterone supplementation in this setting have reported disparate results, likely related to factors such as differences in size, type of progestogen, route of administration, and inclusion of a placebo versus a no treatment arm. When only high quality trials were evaluated by 2016 meta-analysis, maintenance progesterone was not more effective than placebo [35]:

- Delivery <37 weeks: RR 0.91 (95% CI 0.67-1.25)
- Delivery <34 weeks: RR 1.21 (95% CI 0.85-1.70)
- Latency to delivery: RR 0.60 (95% CI -3.73 to 4.94)

A randomized trial that evaluated use of [progesterone](#) (vaginal progesterone or intramuscular [hydroxyprogesterone caproate](#)) after an episode of threatened preterm labor specifically in women with a short cervix also reported no reduction in preterm birth with either drug compared with untreated women [36].

**Singleton pregnancy with spontaneous twin preterm birth in prior pregnancy** — A prior preterm birth is a risk factor for a subsequent preterm birth whether the initial preterm delivery was a singleton or a twin

pregnancy [37-40]. No study has specifically evaluated whether [progesterone](#) supplementation decreases the risk of a preterm birth of a singleton after a previous preterm birth of twins, but a benefit is plausible. The author provides [hydroxyprogesterone caproate](#) supplementation for women with a singleton pregnancy who have had a prior preterm birth, singleton or twin. Not providing progesterone supplementation in this setting is also reasonable.

**Multiple gestations** — [Progesterone](#) is not effective in unselected multiple gestations. One reason may be that the pathogenesis of preterm labor and delivery in multiples is different from that in singletons and less impacted by changes in progesterone.

### Twin pregnancy

- **Unselected twin pregnancies** – In a 2017 meta-analysis of unselected twin gestations randomly assigned to receive [progesterone](#) supplementation (intramuscular or vaginal) or no treatment/placebo (17 trials, n = 4773 women), neither [hydroxyprogesterone caproate](#) nor vaginal progesterone reduced the risk of preterm birth <28, <34, or <37 weeks or improved neonatal outcomes [41]. Administration of a high versus a low dose did not appear to be a factor. These findings generally agree with those from a previous meta-analysis that used individual patient data [42].
- **Twins in current pregnancy and prior singleton preterm birth** – The optimum management of a woman with a prior singleton preterm birth who now has a twin pregnancy with normal cervical length is unclear. A prior preterm birth of a singleton is an independent and additive risk factor for preterm birth of twins [43]. In the absence of data clearly showing harm or lack of efficacy in this specific setting, the author prescribes [hydroxyprogesterone caproate](#) to women with twin pregnancies who have had a previous unexplained spontaneous singleton preterm birth. However, this is controversial [44]. Not providing [progesterone](#) supplementation in this setting is also reasonable. A subgroup analysis of a meta-analysis using individual patient data found that vaginal progesterone was not effective in this setting, although data were limited; no data on hydroxyprogesterone caproate in this setting was available [42].
- **Twin pregnancy with short cervix** – In a 2017 meta-analysis of individual patient data from six randomized trials of women with twin gestations and midtrimester cervical length  $\leq 25$  mm, vaginal [progesterone](#) reduced preterm birth <33 weeks compared with no treatment/placebo (relative risk [RR] 0.69, 95% CI 0.51-0.93; 50/159 [31 percent] versus 62/144 [43 percent]) [45]. The relative risks of neonatal death, respiratory distress syndrome, and birth weight <1500 g were also reduced significantly, on average by 30 to 50 percent. Based on these data, which should be confirmed in larger trials, the author treats twin pregnancies with a short cervix with vaginal progesterone. This is also controversial as the trials have involved a relatively small number of participants. Not providing progesterone supplementation in this setting is also reasonable.

Intramuscular [hydroxyprogesterone caproate](#) does not appear to be beneficial for managing twin pregnancies with a short cervix. In a randomized trial, twice weekly injections of 500 mg hydroxyprogesterone caproate did not result in a reduction in preterm birth (<37, <34, or <32 weeks) or neonatal morbidity/mortality in women with twin pregnancy and a short cervix [46]. In fact, intramuscular hydroxyprogesterone caproate may increase adverse perinatal outcome in twin pregnancy [41,42,47].

**Triplet pregnancy** — A 2015 individual patient data meta-analysis of three placebo-controlled randomized trials of [hydroxyprogesterone caproate](#) supplementation of asymptomatic women with triplet pregnancies reported no benefit [48]. Supplementation did not result in a statistical reduction in preterm birth <28, 32, or 34 weeks or composite adverse perinatal outcome.

**Uterine anomaly or ART** — There are no data on the effectiveness of [progesterone](#) therapy for prevention of preterm birth in women with uterine malformations or who conceive with assisted reproductive technology (ART) [49].

**Maternal obesity** — In women with a pre-pregnancy body mass index (BMI)  $>30 \text{ kg/m}^2$ , a secondary analysis of data from the Maternal-Fetal Medicine Units Network Trial discussed above [3] suggested that [hydroxyprogesterone caproate](#) may not prevent recurrent preterm birth  $<37$  weeks (RR of preterm birth 1.55, 95% CI 0.83-2.89) [50]. The threshold for efficacy appeared to be  $<165$  pounds (74.8 kg). While this report has several weaknesses (eg, it was an unplanned post hoc analysis, pre-pregnancy weights were self-reported, no data were available on weight gain during pregnancy or hydroxyprogesterone caproate serum levels), it raises an important clinical question that needs to be addressed further. Until additional confirmatory studies are available, this author would suggest not limiting hydroxyprogesterone caproate supplementation by any BMI or weight criteria.

**SAFETY, SIDE EFFECTS, AND ADVERSE EFFECTS** — The OPPTIMUM study suggests that [progesterone](#) supplementation for preterm birth prophylaxis does not increase the risk of any major complication in women or offspring up to two years of age [25].

Minor side effects are related to the route of administration, and include injection site reactions and vaginal irritation or discharge. Specific side effects related to synthetic versus natural [progesterone](#) are described below. (See '[Hydroxyprogesterone caproate](#)' below and '[Natural or micronized progesterone](#)' below.)

The package inserts of all [progesterone](#) preparations and progestins in the United States carry a warning that a history of or current thrombophlebitis or venous thromboembolic disorders is a contraindication to use. The US Food and Drug Administration requires this warning because estrogen-progestin contraceptives are associated with an increased risk of venous thrombosis and they believe there is inadequate information to determine whether specific progesterone preparations or progestins are also associated with an increased risk. We use progesterone to reduce the risk of spontaneous preterm birth, when indicated, in women with a history of venous thrombosis as there is no clinical evidence that vaginal progesterone or [hydroxyprogesterone caproate](#) are associated with an increased risk of venous thrombosis.

**CHOICE OF PROGESTERONE PREPARATION** — We recommend [hydroxyprogesterone caproate](#) 250 mg weekly (also known as 17-alpha-hydroxyprogesterone caproate or 17OHP) administered intramuscularly for women with a history of preterm birth and natural [progesterone](#) 100 mg daily administered vaginally for women with a short cervix ( $\leq 20$  mm), based on the outcomes reported in the trials described above. This recommendation is consistent with that of the Society of Maternal Fetal Medicine [51].

Although a 2017 meta-analysis of randomized trials of intramuscular [hydroxyprogesterone caproate](#) or vaginal [progesterone](#) in women with a previous spontaneous preterm birth found that vaginal progesterone resulted in lower rates of spontaneous preterm birth  $<34$  weeks (17.5 versus 25.0 percent; RR 0.71 95% CI 0.53-0.95) [52], this analysis does not influence our approach as it included only three small trials ( $n = 680$  women) and the quality of evidence was low. However, the reproductive effects of the two drugs are not identical [31] and more large comparative trials are needed to determine whether one drug is superior to the other for all pregnancies at high risk for preterm birth, whether the choice of drug should depend on the specific risk factor for preterm birth (past history or short cervix), and whether the different outcomes observed in this trial were due to differences in dosing, formulation, or route of delivery [18,20,53].

Different progesterones may have different clinical effectiveness because synthetic [hydroxyprogesterone caproate](#) and natural [progesterone](#) have different biological activities in the myometrium and uterine cervix: Progesterone decreases myometrial contractility and prevents cervical ripening, but hydroxyprogesterone caproate does not [54]. There also appear to be differential effects on prevention of membrane weakening and, in turn, preterm premature rupture of membranes.

**INITIATION AND DISCONTINUATION OF THERAPY** — Based on the data from randomized trials presented above (see '[Pregnancies likely to benefit from progesterone supplementation](#)' above):

- In women with a previous preterm birth, we begin 17OHP in the second trimester (16 to 20 weeks) and continue the drug through 36+6 weeks of gestation. Ideally, [progesterone](#) is started earlier rather than later within this range for maximum effect [55]. We also follow their cervical length with serial ultrasound

examinations until 24 weeks of gestation, and consider cerclage if cervical length is  $\leq 25$  mm. (See "[Cervical insufficiency](#)", [section on 'Ultrasound-based cervical insufficiency'](#).)

- In women with no previous preterm birth and a short cervix  $\leq 20$  mm before 24 weeks, we begin natural [progesterone](#) upon diagnosis and continue the drug through 36+6 weeks of gestation.

## PROGESTERONE PREPARATIONS AND DOSES

**Hydroxyprogesterone caproate** — [Hydroxyprogesterone caproate](#) is a synthetic progestogen with minimal to no androgenic activity. Doses have ranged from 25 mg every five days to 1000 mg weekly, beginning as early as 16 weeks of gestation. We use a 250 mg dose, administered intramuscularly. Standard contraindications to [progesterone](#) administration include hormone-sensitive cancer, liver disease, or uncontrolled hypertension.

The safety of [hydroxyprogesterone caproate](#) in pregnancy has been supported by numerous epidemiologic studies [56-59] and clinical trials [2,3,60]. Although several studies have reported a nonstatistical increase in risk of miscarriage and stillbirth in pregnancies exposed to progestins [3,32,61,62], others could not confirm this observation or observed a nonstatistical decrease in these risks [63-65]. This association requires further study [66].

Another concern is a possible increase in risk of hypospadias in male offspring exposed to exogenous progestins [67,68]; even if confirmed, this risk is limited to exposure prior to 11 weeks of gestation and thus is not relevant to women with prior preterm delivery, as they will receive the drug after 16 weeks of gestation.

Both diabetogenic and anti-diabetogenic effects have been attributed to [progesterone](#). Weekly use of [hydroxyprogesterone caproate](#) by women at risk for preterm delivery does not appear to increase their risk for developing gestational diabetes. In a secondary analysis of data from two double-blind randomized placebo-controlled trials of hydroxyprogesterone caproate for prevention of preterm delivery, the incidence of gestational diabetes was similar in the intervention and placebo groups [69]. An observational study reported discordant findings, which may have been due to differences in patient characteristics (eg, race, ethnicity) between women who did and did not receive hydroxyprogesterone caproate [70].

Makena (United States brand name) is a [hydroxyprogesterone caproate](#) preparation approved by the US Food and Drug Administration to reduce the risk of recurrent preterm birth in women with a singleton pregnancy who have a history of a prior spontaneous preterm delivery [71]. Two methods for delivery are available: an autoinjector for subcutaneous administration of 275 mg and single- and multi-dose vials for intramuscular injection of 250 mg. Physicians may request a licensed pharmacist to compound a hydroxyprogesterone caproate preparation tailored to an individual patient's particular medical needs, but should be aware of regulations and spectrum of quality concerns related to this practice [72-76].

**Natural or micronized progesterone** — Natural [progesterone](#) is typically administered vaginally. The advantage of vaginal progesterone is its high uterine bioavailability since uterine exposure occurs before the first pass through the liver. Natural progesterone also has greater binding affinity for nuclear progesterone receptors than hydroxyprogesterone acetate [77]. It also has few systemic side effects, but vaginal irritation can be bothersome and the drug needs to be administered daily. Doses of 90 to 400 mg have been effective, beginning as early as 18 weeks of gestation. We use 100 mg administered vaginally each evening; however, in some areas a 200 mg suppository may be more readily available and less costly. A vaginal suppository can be prepared by a compounding pharmacy utilizing a commercially available standardized kit [78].

Other options include a 100 mg micronized [progesterone](#) vaginal tablet or an 8 percent vaginal gel containing 90 mg micronized progesterone per dose. Both preparations are commercially available in the United States, but not approved for prevention of preterm birth in cervical shortening. The FDA concluded the data in the manufacturer's application did not sufficiently support the efficacy of progesterone 8 percent gel compared with placebo in reducing the risk of preterm births before 33 completed weeks of gestation among women with a short cervical length, but the drug was safe in this population [79]. The FDA was critical of the



statistical methods used in the key trial and noted that most of the apparent treatment benefit occurred in non-US centers. The safety profile of vaginal progesterone in the first trimester of pregnancy is supported by extensive data from patients who received the drug for luteal support, while large trials during the second and third trimester in women at increased risk of preterm birth support its safety later in gestation [25,80,81].

**Oral progesterone** — An oral micronized preparation of natural [progesterone](#) also exists. Daily doses of 900 to 1600 mg have been given. Reported side effects include sleepiness, fatigue and headache [60,82].

**SOCIETY GUIDELINE LINKS** — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "[Society guideline links: Preterm labor and birth](#)".)

## SUMMARY AND RECOMMENDATIONS

- [Progesterone](#) supplementation reduces the risk of preterm birth by about one-third in women with a singleton pregnancy who have had a previous spontaneous singleton preterm birth and in women with a short cervix on ultrasound examination in the current pregnancy. (See '[Pregnancies likely to benefit from progesterone supplementation](#)' above.)
- For women with a singleton pregnancy who have had a previous spontaneous singleton preterm birth, we suggest [progesterone](#) treatment (**Grade 2B**). We suggest intramuscular injections of [hydroxyprogesterone caproate](#) rather than vaginal progesterone (**Grade 2C**), beginning in the second trimester (16 to 20 weeks) and continuing through 36+6 weeks of gestation. We prescribe 250 mg weekly. Daily natural progesterone administered vaginally is a reasonable alternative. (See '[Spontaneous singleton preterm birth in prior pregnancy](#)' above.) We also follow their cervical length with serial ultrasound examinations until 24 weeks of gestation, and consider cerclage if cervical length is  $\leq 25$  mm. (See "[Cervical insufficiency](#)", [section on 'Ultrasound-based cervical insufficiency'](#)".)

We manage women with a singleton pregnancy who have had a prior spontaneous preterm twin birth the same way. (See '[Singleton pregnancy with spontaneous twin preterm birth in prior pregnancy](#)' above.)

- For women with midtrimester cervical shortening (defined as  $\leq 20$  mm before 24 weeks) and no prior spontaneous singleton preterm birth, we suggest daily vaginal [progesterone](#) treatment (**Grade 2B**) through 36+6 weeks of gestation. Reasonable options include a vaginal suppository (100 or 200 mg), gel (90 mg), or tablet (100 mg micronized progesterone). (See '[Short cervix in current pregnancy](#)' above and '[Choice of progesterone preparation](#)' above.)
- For multiple gestations, we recommend not administering [progesterone](#) supplementation routinely (**Grade 1B**) (see '[Multiple gestations](#)' above). However:
  - For women with twin pregnancies and a previous spontaneous preterm birth, the author prescribes [hydroxyprogesterone caproate](#). Not prescribing [progesterone](#) supplementation or prescribing natural progesterone vaginally is also reasonable. (See '[Twin pregnancy](#)' above.)
  - For women with twin pregnancies and a short cervix in the current pregnancy, the author prescribes vaginal [progesterone](#). Not prescribing progesterone supplementation is also reasonable. (See '[Twin pregnancy](#)' above.)
- Routine [progesterone](#) supplementation does not appear to be useful for preventing preterm birth in the setting of preterm premature rupture of membranes or after an episode of arrested preterm labor. There is no information on efficacy in women with a positive fetal fibronectin test. The effect in women with a cerclage is unclear. (See '[Preterm premature rupture of membranes](#)' above and '[Positive fetal fibronectin test](#)' above and '[Cerclage](#)' above and '[Threatened preterm labor](#)' above.)
- For women who choose to take [progesterone](#) for preterm birth prophylaxis, it appears to be safe with no major adverse events noted in follow-up studies up to two years. (See '[Safety, side effects, and adverse](#)

[effects'](#) above.)

Use of UpToDate is subject to the [Subscription and License Agreement](#).

## REFERENCES

1. Petrini JR, Callaghan WM, Klebanoff M, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. *Obstet Gynecol* 2005; 105:267.
2. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. *Am J Obstet Gynecol* 2003; 188:419.
3. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. *N Engl J Med* 2003; 348:2379.
4. Norman JE, Bennett P. Preterm birth prevention-Time to PROGRESS beyond progesterone. *PLoS Med* 2017; 14:e1002391.
5. Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. *Obstet Gynecol Surv* 1978; 33:69.
6. Peyron R, Aubény E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. *N Engl J Med* 1993; 328:1509.
7. Norwitz ER, Robinson JN, Challis JR. The control of labor. *N Engl J Med* 1999; 341:660.
8. Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. *Endocr Rev* 2000; 21:514.
9. Norwitz ER, Lye SJ. Biology of parturition. In: Creasy RK, Resnick R, Iams JD, et al, eds. *Creasy & Resnick's Maternal-Fetal Medicine*, 6th ed. Philadelphia: Elsevier; 2009:69-85.
10. Condon JC, Jeyasuria P, Faust JM, et al. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. *Proc Natl Acad Sci U S A* 2003; 100:9518.
11. Oh SY, Kim CJ, Park I, et al. Progesterone receptor isoform (A/B) ratio of human fetal membranes increases during term parturition. *Am J Obstet Gynecol* 2005; 193:1156.
12. Renthal NE, Chen CC, Williams KC, et al. miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor. *Proc Natl Acad Sci U S A* 2010; 107:20828.
13. Mesiano S, Wang Y, Norwitz ER. Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? *Reprod Sci* 2011; 18:6.
14. Lockwood CJ, Stocco C, Murk W, et al. Human labor is associated with reduced decidual cell expression of progesterone, but not glucocorticoid, receptors. *J Clin Endocrinol Metab* 2010; 95:2271.
15. Luo G, Abrahams VM, Tadesse S, Funai EF, Hodgson EJ, Gao J, Norwitz ER. Progesterone inhibits basal and TNF $\alpha$ -induced apoptosis in fetal membranes: A novel mechanism to explain progesterone-mediated prevention of preterm birth. *Reprod. Sci* 2010; 17:532.
16. Kumar D, Springel E, Moore RM, et al. Progesterone inhibits in vitro fetal membrane weakening. *Am J Obstet Gynecol* 2015; 213:520.e1.
17. O'Brien JM, Lewis DF. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety. *Am J Obstet Gynecol* 2016; 214:45.
18. Kuon RJ, Shi SQ, Maul H, et al. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. *Am J Obstet*

- Gynecol 2010; 202:455.e1.
19. O'Sullivan MD, Hehir MP, O'Brien YM, Morrison JJ. 17 alpha-hydroxyprogesterone caproate vehicle, castor oil, enhances the contractile effect of oxytocin in human myometrium in pregnancy. *Am J Obstet Gynecol* 2010; 202:453.e1.
  20. Caritis SN, Venkataramanan R, Thom E, et al. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. *Am J Obstet Gynecol* 2014; 210:128.e1.
  21. Manuck TA, Esplin MS, Biggio J, et al. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth. *Am J Obstet Gynecol* 2016; 214:376.e1.
  22. Manuck TA, Stoddard GJ, Fry RC, et al. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system. *Am J Obstet Gynecol* 2016; 215:622.e1.
  23. Manuck TA, Lai Y, Meis PJ, et al. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. *Am J Obstet Gynecol* 2011; 205:135.e1.
  24. Dodd JM, Jones L, Flenady V, et al. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. *Cochrane Database Syst Rev* 2013; :CD004947.
  25. Norman JE, Marlow N, Messow CM, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. *Lancet* 2016; 387:2106.
  26. Spong CY, Meis PJ, Thom EA, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. *Am J Obstet Gynecol* 2005; 193:1127.
  27. Crowther CA, Ashwood P, McPhee AJ, et al. Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial. *PLoS Med* 2017; 14:e1002390.
  28. Romero R, Conde-Agudelo A, Da Fonseca E, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. *Am J Obstet Gynecol* 2018; 218:161.
  29. Grobman WA, Thom EA, Spong CY, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. *Am J Obstet Gynecol* 2012; 207:390.e1.
  30. Winer N, Bretelle F, Senat MV, et al. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. *Am J Obstet Gynecol* 2015; 212:485.e1.
  31. Romero R, Yeo L, Chaemsaihong P, et al. Progesterone to prevent spontaneous preterm birth. *Semin Fetal Neonatal Med* 2014; 19:15.
  32. Briery CM, Veillon EW, Klauser CK, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. *Am J Obstet Gynecol* 2011; 204:54.e1.
  33. Combs CA, Garite TJ, Maurel K, et al. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial. *Am J Obstet Gynecol* 2015; 213:364.e1.
  34. Su LL, Samuel M, Chong YS. Progesterone agents for treating threatened or established preterm labour. *Cochrane Database Syst Rev* 2014; :CD006770.
  35. Palacio M, Ronzoni S, Sánchez-Ramos L, Murphy KE. Progestogens as Maintenance Treatment in Arrested Preterm Labor: A Systematic Review and Meta-analysis. *Obstet Gynecol* 2016; 128:989.
  36. Facchinetti F, Vergani P, Di Tommaso M, et al. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial. *Obstet Gynecol* 2017; 130:64.
  37. Schaaf JM, Hof MH, Mol BW, et al. Recurrence risk of preterm birth in subsequent twin pregnancy after preterm singleton delivery. *BJOG* 2012; 119:1624.

38. Rafael TJ, Hoffman MK, Leiby BE, Berghella V. Gestational age of previous twin preterm birth as a predictor for subsequent singleton preterm birth. *Am J Obstet Gynecol* 2012; 206:156.e1.
39. Schaaf JM, Hof MH, Mol BW, et al. Recurrence risk of preterm birth in subsequent singleton pregnancy after preterm twin delivery. *Am J Obstet Gynecol* 2012; 207:279.e1.
40. Facco FL, Nash K, Grobman WA. Are women who have had a preterm twin delivery at greater risk of preterm birth in a subsequent singleton pregnancy? *Am J Obstet Gynecol* 2007; 197:253.e1.
41. Dodd JM, Grivell RM, O'Brien CM, et al. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. *Cochrane Database Syst Rev* 2017; 10:CD012024.
42. Schuit E, Stock S, Rode L, et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis. *BJOG* 2015; 122:27.
43. Ananth CV, Kirby RS, Vintzileos AM. Recurrence of preterm birth in twin pregnancies in the presence of a prior singleton preterm birth. *J Matern Fetal Neonatal Med* 2008; 21:289.
44. Durnwald CP. 17 OHPC for prevention of preterm birth in twins: back to the drawing board? *Am J Obstet Gynecol* 2013; 208:167.
45. Romero R, Conde-Agudelo A, El-Refaie W, et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. *Ultrasound Obstet Gynecol* 2017; 49:303.
46. Senat MV, Porcher R, Winer N, et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. *Am J Obstet Gynecol* 2013; 208:194.e1.
47. Romero R, Conde-Agudelo A. Is 17 $\alpha$ -hydroxyprogesterone caproate contraindicated in twin gestations? *BJOG* 2015; 122:6.
48. Combs CA, Schuit E, Caritis SN, et al. 17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis. *BJOG* 2016; 123:682.
49. Likis FE, Andrews JC, Woodworth AL, et al. Progestogens for Prevention of Preterm Birth. Comparative Effectiveness Review No. 74. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I). AHRQ Publication No. 12-EHC105-EF. Rockville, MD: Agency for Healthcare Research and Quality. September 2012. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).
50. Heyborne KD, Allshouse AA, Carey JC. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women? *Am J Obstet Gynecol* 2015; 213:844.e1.
51. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. *Am J Obstet Gynecol* 2017; 216:B11.
52. Saccone G, Khalifeh A, Elimian A, et al. Vaginal progesterone vs intramuscular 17 $\alpha$ -hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials. *Ultrasound Obstet Gynecol* 2017; 49:315.
53. Romero R, Stanczyk FZ. Progesterone is not the same as 17 $\alpha$ -hydroxyprogesterone caproate: implications for obstetrical practice. *Am J Obstet Gynecol* 2013; 208:421.
54. Kumar D, Moore RM, Mercer BM, et al. In an in-vitro model using human fetal membranes, 17- $\alpha$  hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening. *Am J Obstet Gynecol* 2017; 217:695.e1.
55. Ning A, Vladutiu CJ, Dotters-Katz SK, et al. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth. *Am J Obstet Gynecol* 2017; 217:371.e1.

56. Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. *Teratology* 1980; 22:251.
57. Resseguie LJ, Hick JF, Bruen JA, et al. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974. *Fertil Steril* 1985; 43:514.
58. Raman-Wilms L, Tseng AL, Wighardt S, et al. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. *Obstet Gynecol* 1995; 85:141.
59. Northen AT, Norman GS, Anderson K, et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. *Obstet Gynecol* 2007; 110:865.
60. O'Brien JM, Adair CD, Lewis DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2007; 30:687.
61. Rouse DJ, Caritis SN, Peaceman AM, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. *N Engl J Med* 2007; 357:454.
62. Norman JE, Mackenzie F, Owen P, et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. *Lancet* 2009; 373:2034.
63. Combs CA, Garite T, Maurel K, et al. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. *Am J Obstet Gynecol* 2011; 204:221.e1.
64. Caritis SN, Rouse DJ, Peaceman AM, et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. *Obstet Gynecol* 2009; 113:285.
65. Berghella V, Figueroa D, Szychowski JM, et al. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. *Am J Obstet Gynecol* 2010; 202:351.e1.
66. US Food and Drug Administration, Center for Drug Evaluation and Research. Summary minutes of the Advisory Committee for Reproductive Health Drugs, August 29, 2006. <http://www.fda.gov/ohrms/docket/ac/06/minutes/2006-4227M1.pdf> (accessed June 30, 2011).
67. Silver RI, Rodriguez R, Chang TS, Gearhart JP. In vitro fertilization is associated with an increased risk of hypospadias. *J Urol* 1999; 161:1954.
68. Carmichael SL, Shaw GM, Laurent C, et al. Maternal progestin intake and risk of hypospadias. *Arch Pediatr Adolesc Med* 2005; 159:957.
69. Gyamfi C, Horton AL, Momirova V, et al. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. *Am J Obstet Gynecol* 2009; 201:392.e1.
70. Rebarber A, Istwan NB, Russo-Stieglitz K, et al. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. *Diabetes Care* 2007; 30:2277.
71. Statement on Makena [press release]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; March 30, 2011. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm249025.htm> (accessed on May 9, 2011).
72. Chang J, Zhao Y, Zhao W, et al. Quality assessment of compounded 17-hydroxyprogesterone caproate. *Am J Obstet Gynecol* 2014; 210:47.e1.
73. <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm402614.htm> (Accessed on March 16, 2017).
74. <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm308546.htm> (Accessed on March 16, 2017).
75. <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310215.htm> (Accessed on March 16, 2017).

76. Fried I, Beam AL, Kohane IS, Palmer NP. Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth. *JAMA Intern Med* 2017; 177:1689.
77. Attardi BJ, Zeleznik A, Simhan H, et al. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. *Am J Obstet Gynecol* 2007; 197:599.e1.
78. [www.cutispharma.com](http://www.cutispharma.com).
79. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs. January 20, 2012. NDA 22-139. Progesterone gel (8%) <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM287987.pdf>.
80. Fonseca EB, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short cervix. *N Engl J Med* 2007; 357:462.
81. Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2011; 38:18.
82. Thornton JG. Progesterone and preterm labor--still no definite answers. *N Engl J Med* 2007; 357:499.

Topic 16560 Version 90.0

## GRAPHICS

### Recommendations for progesterone supplementation to prevent preterm birth

Indication	Progesterone supplementation indicated?	Management
Singleton pregnancy, prior spontaneous singleton preterm birth, normal cervical length	Yes	<p>Hydroxyprogesterone caproate 250 mg intramuscularly weekly beginning between 16 and 20 weeks of gestation and continuing through 36 weeks of gestation or until delivery and monitor cervical length. Natural progesterone administered vaginally is a reasonable alternative.</p> <p>Short (&lt;25 mm) cervix → consider performing cerclage</p>
Singleton pregnancy, prior spontaneous twin preterm birth, normal cervical length	Possibly	<p>Hydroxyprogesterone caproate 250 mg intramuscularly weekly beginning between 16 and 20 weeks of gestation and continuing through 36 weeks of gestation or until delivery and monitor cervical length. Natural progesterone administered vaginally is a reasonable alternative.</p> <p>Short (&lt;25 mm) cervix → consider performing cerclage</p>
Singleton pregnancy, no prior spontaneous preterm birth, short cervix ( $\leq 20$ mm)	Yes	<p>Progesterone suppository 90 to 200 mg vaginally each night from time of diagnosis through 36 weeks of gestation.</p> <p>A vaginal suppository can be prepared by a compounding pharmacy utilizing a commercially available standardized kit.</p> <p>Other options include a 100 mg micronized progesterone vaginal tablet or an 8 percent vaginal gel containing 90 mg micronized progesterone per dose. Both preparations are commercially available in US, but not approved for prevention of preterm birth in cervical shortening.</p>
Multiple pregnancy (twins or triplets) without prior preterm birth, normal cervical length	No	No progesterone, no cerclage
Twins, prior preterm birth	Possibly	Hydroxyprogesterone caproate

		250 mg intramuscularly weekly beginning between 16 and 20 weeks of gestation and continuing through 36 weeks of gestation or until delivery. Natural progesterone administered vaginally is a reasonable alternative.
Twins, short cervix	Possibly	Vaginal progesterone, no cerclage
Preterm premature rupture of membranes	No	–
Positive fetal fibronectin test	No	–
Undelivered after an episode of preterm labor	No	–

Graphic 66456 Version 12.0



## Contributor Disclosures

**Errol R Norwitz, MD, PhD, MBA** Grant/Research/Clinical Trial Support: Illumina [Preeclampsia (primary investigator on a prospective cohort study to collect samples from patients with preeclampsia to facilitate development of a biomarker test to predict/diagnose this disorder)]. Consultant/Advisory Boards: Hologic [Preterm birth (Fetal fibronectin test to predict preterm birth)]; Natera [Fetal aneuploidy testing (NIPT as a screening test for fetal aneuploidy)]; Seracare [Fetal aneuploidy testing (Developing controls for NIPT screening test for fetal aneuploidy)]; Bayer [Prediction test for preeclampsia (Use of urinary angiogenic factors to predict preeclampsia)]. **Charles J Lockwood, MD, MHCM** Nothing to disclose **Vanessa A Barss, MD, FACOG** Nothing to disclose

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

[Conflict of interest policy.](#)